Zhejiang Huakang Pharmaceutical Co Ltd (SHG:605077) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Huakang Pharmaceutical Co Ltd (605077)
Zhejiang Huakang Pharmaceutical Co Ltd (SHG:605077) has a market capitalization of $478.05 Million (CN¥3.27 Billion) as of August 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #12555 globally and #3646 in its home market, demonstrating a -1.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Huakang Pharmaceutical Co Ltd's stock price CN¥10.78 by its total outstanding shares 303049811 (303.05 Million). Check Zhejiang Huakang Pharmaceutical Co Ltd (605077) stock price for real-time trading data and today's change.
Zhejiang Huakang Pharmaceutical Co Ltd Market Cap History: 2021 to 2026
Zhejiang Huakang Pharmaceutical Co Ltd's market capitalization history from 2021 to 2026. Data shows change from $930.67 Million to $478.05 Million (-14.87% CAGR).
Zhejiang Huakang Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Huakang Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Zhejiang Huakang Pharmaceutical Co Ltd net assets to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
0.23x
Zhejiang Huakang Pharmaceutical Co Ltd's market cap is 0.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.43x
Zhejiang Huakang Pharmaceutical Co Ltd's market cap is 2.43 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $930.67 Million | $1.59 Billion | $236.71 Million | 0.58x | 3.93x |
| 2022 | $972.38 Million | $2.20 Billion | $319.28 Million | 0.44x | 3.05x |
| 2023 | $708.40 Million | $2.78 Billion | $371.45 Million | 0.25x | 1.91x |
| 2024 | $652.77 Million | $2.81 Billion | $268.48 Million | 0.23x | 2.43x |
Competitor Companies of 605077 by Market Capitalization
Companies near Zhejiang Huakang Pharmaceutical Co Ltd in the global market cap rankings as of August 24, 2026. Also see Zhejiang Huakang Pharmaceutical Co Ltd (605077) cash conversion ratio for how efficiently the company converts equity into cash flow.
Key companies related to Zhejiang Huakang Pharmaceutical Co Ltd by market ranking:
- BASF SE (F:BASA): Ranked #606 globally with a market cap of $45.63 Billion USD ( €39.03 Billion EUR).
- BASF SE (XETRA:BAS): Ranked #626 globally with a market cap of $44.13 Billion USD ( €37.75 Billion EUR).
- Ningxia Baofeng Energy Group Co Ltd (SHG:600989): Ranked #1053 globally with a market cap of $25.82 Billion USD ( CN¥176.44 Billion CNY).
- Dow Inc (NYSE:DOW): Ranked #1151 globally with a market cap of $23.32 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #606 | BASF SE | F:BASA | $45.63 Billion | €13.20 |
| #626 | BASF SE | XETRA:BAS | $44.13 Billion | €51.67 |
| #1053 | Ningxia Baofeng Energy Group Co Ltd | SHG:600989 | $25.82 Billion | CN¥24.06 |
| #1151 | Dow Inc | NYSE:DOW | $23.32 Billion | $32.35 |
Zhejiang Huakang Pharmaceutical Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Zhejiang Huakang Pharmaceutical Co Ltd's market cap moved from $930.67 Million to $ 478.05 Million, with a yearly change of -14.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥478.05 Million | -27.06% |
| 2025 | CN¥655.43 Million | +0.41% |
| 2024 | CN¥652.77 Million | -7.85% |
| 2023 | CN¥708.40 Million | -27.15% |
| 2022 | CN¥972.38 Million | +4.48% |
| 2021 | CN¥930.67 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of Zhejiang Huakang Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $478.05 Million USD |
| MoneyControl | $478.05 Million USD |
| MarketWatch | $478.05 Million USD |
| marketcap.company | $478.05 Million USD |
| Reuters | $478.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Huakang Pharmaceutical Co Ltd
Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols and starch sugar worldwide. It offers polyols products such as xylitol, is a polyol that occurs naturally regular sugar raise blood sugar levels; sorbitol, is produced by the catalytic hydrogenation of D-glucose and is available as a free-flowing crystalline powder, and as aqueous solutions; maltito… Read more